| Drug Name |
Halcinonide |
| Drug ID |
BADD_D01050 |
| Description |
Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of psoriasis when compared to halcinonide. |
| Indications and Usage |
Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
D07AD02 |
| DrugBank ID |
DB06786
|
| KEGG ID |
D01308
|
| MeSH ID |
D006206
|
| PubChem ID |
443943
|
| TTD Drug ID |
D06IIB
|
| NDC Product Code |
10631-096; 71428-011; 0378-8056; 0003-0249; 46439-8717; 57664-698 |
| UNII |
SI86V6QNEG
|
| Synonyms |
Halcinonide | Alcinonide | Halciderm | Halcimat | Halog | Dermalog | SQ-18,566 | SQ 18,566 | SQ18,566 |
